Advocacy intelligence hub — real-time data for patient organizations
Hangzhou Yirui Pharmaceutical Technology Co., Ltd — PHASE1
Duke University — NA
Akebia Therapeutics — PHASE1
Oregon Health and Science University — NA
AC Immune SA — PHASE1
Alcamena Stem Cell Therapeutics — PHASE1
Bristol-Myers Squibb — PHASE1
Synphatec (Shanghai) Biopharmaceutical Technology Co., Ltd. — PHASE1
Gottsegen National Cardiovascular Institute — NA
1ST Biotherapeutics, Inc. — PHASE1
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Wenbin Li
Beijing Tiantan Hospital
Sheffali Gulati, MD
All India Institute of Medical Sciences
Central Contact
Astellas Pharma Global Development
Dale Christensen, PhD
TFF Pharmaceuticals
Mohamed Al-Ibrahim, MD
SNBL
📍 BALTIMORE, MD
David S Ditor, PhD
Brock University